



Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA
02210-1862
Tel: 617-341-6100
www.vrtx.com

Notice Regarding Adjustment of 340B Prices for Select Products of Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated “Vertex” has recalculated its 340B ceiling price for the period Q1 2025 for the products listed below due to the recalculation of an estimated provisional 340B ceiling price. Vertex has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this notice on the public website to ensure transparency by providing access to information about Vertex’s recalculation affecting certain 340B Covered Entities for the impacted product(s).

Vertex has determined the credit amount owed to each affected covered entity. Vertex will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity’s validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified.

NDC	Product Description
51167-0548-30	JOURNAVX™ (suzetrigine 50MG), 30ct
51167-0121-01	ALYFTREK® (vanzacator 10 mg/tezacator 50 mg/deutivacator 125 mg)
51167-0135-01	ALYFTREK® (vanzacator 4 mg/tezacator 20 mg/deutivacator 50 mg)

If a Covered Entity believes they are due a refund and are not contacted by Apexus by September 30, 2025, you may email Vertex Government Pricing at gov_pricing@vrtx.com.